Merck’s eye drug met the primary endpoint in a pivotal study, but the full results raise questions about its commercial prospects. https://endpoints.news/merck-reports-mixed-data-for-lucentis-competitor-in-diabetic-macular-edema/?utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial